Feeds:
Posts
Comments

Search Results for 'Allergan'

Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D?

Posted in Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, tagged , , , , , , on November 23, 2015| Leave a Comment »


Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D? Curator: Stephen J. Williams, Ph.D. Just recently this site had a post entitled Pfizer Near Allergan Buyout Deal But Will Fed Allow It?  Now, as Bloomberg reports the international deal between Allergan and Pfizer has gone through, resulting in a […]

Read Full Post »

Pfizer Near Allergan Buyout Deal But Will Fed Allow It?

Posted in Pharmaceutical Industry Competitive Intelligence, tagged , , , on November 19, 2015| Leave a Comment »


Pfizer Near Allergan Buyout Deal But Will Fed Allow It?     Reporter: Stephen J. Williams, Ph.D. From Bloomberg Business™ Pfizer Inc. is in advanced talks to buy Allergan Plc for as much as $380 per share, according to people familiar with the matter, valuing the Botox maker at as high as $150 billion — […]

Read Full Post »

M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC

Posted in Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on March 30, 2015| Leave a Comment »


M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC Reporter: Aviva Lev-Ari, PhD, RN The deal, Allergan Inc.’s $66 billion sale to Actavis PLC, closed on 3/22/2015, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman’s hedge-fund firm had […]

Read Full Post »

Allergan agrees to $66 billion Actavis offer $219 a share

Posted in Pharmaceutical Industry Competitive Intelligence on November 17, 2014| Leave a Comment »


Allergan agrees to $66 billion Actavis offer $219 a share Reporter: Aviva Lev-Ari, PhD, RN   (Reuters) – Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc. Dublin-based Actavis offered $219 per share in cash and stock, amounting […]

Read Full Post »

Top 15 pharmas, then=2026 and now=2020: How the next five years will shake up Big Pharma’s rankings

Posted in Pharmaceutical Analytics, Pharmaceutical Industry Competitive Intelligence on July 14, 2020| Leave a Comment »


Top 15 pharmas, then=2026 and now=2020: How the next five years will shake up Big Pharma’s rankings Reporter: Aviva Lev-Ari, PhD, RN   As the pharma industry enters a new decade, the world’s largest drug companies are busy launching new meds, restructuring to focus on innovative offerings and eyeing new technologies. And despite challenges from the COVID-19 pandemic, analysts […]

Read Full Post »

COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response

Posted in Coronavirus Gene Expression, COVID-19, Population Health Management, Genetics & Pharmaceutical, SARS-CoV-2, Serology tests for coronavirus antibodies, Treatment Protocols for COVID-19, Vaccinology, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 29, 2020| Leave a Comment »


COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response Curator: Aviva Lev-Ari, PhD, RN   On 5/26/2020 LPBI organized a Symposium on New Therapeutics for COVID-19 AGENDA included presentations by: Dr. Raphael […]

Read Full Post »

The Impact Of The Coronavirus Crisis On Mergers And Acquisitions

Posted in COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management on April 17, 2020| Leave a Comment »


The Impact Of The Coronavirus Crisis On Mergers And Acquisitions Reporter – Dr. Joel T. Shertok   The Impact Of The Coronavirus Crisis On Mergers And Acquisitions By Richard D. Harroch, David A. Lipkin, and Richard V. Smith Forbes – April 17, 2020 The coronavirus (COVID-19) crisis is having and will continue to have a material global […]

Read Full Post »

Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus

Posted in on March 18, 2020|


Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus Aviva Lev-Ari, PhD, RN – March 14, 2020 to Present Lead Curator, e–mail Contact: AvivaLev-Ari@alum.berkeley.edu Therapeutical options for coronavirus viral infection include the following: (a) Monoclonal and polyclonal antibodies Therapeutic SARS-CoV neutralizing antibodies have been generated and could be retrieved and used again in the event of another […]

Read Full Post »

Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings

Posted in Drug Development Process, Intellectual Property, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, tagged , , , , , , , , , , on June 17, 2019| Leave a Comment »


Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings Reporter: Stephen J. Williams, PhD As reported in FiercePharma.com: by Angus Liu | Jun 17, 2019 11:42am Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology. In the first […]

Read Full Post »

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma

Posted in Cancer - General, Cancer and Current Therapeutics, Drug Development Process, Health Economics and Outcomes Research, Patents, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Uncategorized, tagged , , , , , , , , , on January 25, 2019| Leave a Comment »


From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma   Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes.  It is […]

Read Full Post »

Next »